Related Experiment Video
Updated: May 16, 2026

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
Published on: April 5, 2018
Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules
Pilar Blancafort1, Jian Jin, Stephen Frye
1School of Anatomy, Physiology, and Human Biology, M309, the University of Western Australia, 35 Stirling Highway, Crawley, 6009, WA, Australia. pilar.blancafort@uwa.edu.au
Abstract:
The epigenomic era has revealed a well-connected network of molecular processes that shape the chromatin landscape. These processes comprise abnormal methylomes, transcriptosomes, genome-wide histone post-transcriptional modifications patterns, histone variants, and noncoding RNAs. The mapping of these processes in large scale by chromatin immunoprecipitation sequencing and other methodologies in both cancer and normal cells reveals novel therapeutic opportunities for anticancer intervention. The goal of this minireview is to summarize pharmacological strategies to modify the epigenetic landscape of cancer cells. These approaches include the use of novel small molecule inhibitors of epigenetic processes specifically deregulated in cancer cells and the design of engineered proteins able to stably reprogram the epigenetic code in cancer cells in a way that is similar to normal cells.
Insights
The epigenomic era reveals molecular processes shaping chromatin. This review summarizes pharmacological strategies, including small molecule inhibitors and engineered proteins, to modify the cancer epigenome for therapeutic intervention.
Area of Science:
- Epigenetics and Cancer Biology
- Molecular Oncology
Background:
- The epigenome, including methylomes, transcriptosomes, histone modifications, and noncoding RNAs, plays a crucial role in shaping the chromatin landscape.
- Aberrant epigenetic processes are implicated in cancer development and progression.
- Large-scale mapping of these epigenetic marks in cancer cells has identified novel therapeutic targets.
Purpose of the Study:
- To summarize current pharmacological strategies for modifying the epigenetic landscape in cancer cells.
- To highlight novel therapeutic opportunities arising from epigenomic research.
Main Methods:
- Review of pharmacological approaches targeting epigenetic dysregulation in cancer.
- Discussion of small molecule inhibitors of epigenetic enzymes.
- Exploration of engineered proteins for epigenetic reprogramming.
Main Results:
- Epigenetic modifications are key targets for anticancer therapies.
- Small molecule inhibitors offer a strategy to correct aberrant epigenetic marks.
- Engineered proteins show potential for stable epigenetic reprogramming.
Conclusions:
- Pharmacological modulation of the epigenome represents a promising avenue for cancer treatment.
- Targeting specific epigenetic alterations in cancer cells can lead to effective therapeutic interventions.
- Future research should focus on developing precise and stable epigenetic reprogramming strategies.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Epigenetic Regulation
Cancer
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

